Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury.
Endoplasmic reticulum (ER) stress is associated with acute kidney injury (AKI) caused by various mechanisms, including antibiotics, non-steroidal anti-inflammatory drugs, cisplatin, and radiocontrast. Tunicamycin (TM) is a nucleoside antibiotic that induces ER stress and is a commonly used model of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0260519 |
| _version_ | 1818964151372873728 |
|---|---|
| author | Rachel E Carlisle Salwa Farooqi Ming Chan Zhang Sarah Liu Chao Lu Andy Phan Elise Brimble Jeffrey G Dickhout |
| author_facet | Rachel E Carlisle Salwa Farooqi Ming Chan Zhang Sarah Liu Chao Lu Andy Phan Elise Brimble Jeffrey G Dickhout |
| author_sort | Rachel E Carlisle |
| collection | DOAJ |
| description | Endoplasmic reticulum (ER) stress is associated with acute kidney injury (AKI) caused by various mechanisms, including antibiotics, non-steroidal anti-inflammatory drugs, cisplatin, and radiocontrast. Tunicamycin (TM) is a nucleoside antibiotic that induces ER stress and is a commonly used model of AKI. 4-phenylbutyrate (4-PBA) is a chemical chaperone and histone deacetylase (HDAC) inhibitor and has been shown to protect the kidney from ER stress, apoptosis, and structural damage in a tunicamycin model of AKI. The renal protection provided by 4-PBA is attributed to its ability to prevent misfolded protein aggregation and inhibit ER stress; however, the HDAC inhibitor effects of 4-PBA have not been examined in the TM-induced model of AKI. As such, the main objective of this study was to determine if histone hyperacetylation provides any protective effects against TM-mediated AKI. The FDA-approved HDAC inhibitor vorinostat was used, as it has no ER stress inhibitory effects and therefore the histone hyperacetylation properties alone could be investigated. In vitro work demonstrated that vorinostat inhibited histone deacetylation in cultured proximal tubular cells but did not prevent ER stress or protein aggregation induced by TM. Vorinostat induced a significant increase in cell death, and exacerbated TM-mediated total cell death and apoptotic cell death. Wild type male mice were treated with TM (0.5 mg/kg, intraperitoneal injection), with or without vorinostat (50 mg/kg/day) or 4-PBA (1 g/kg/day). Mice treated with 4-PBA or vorinostat exhibited similar levels of histone hyperacetylation. Expression of the pro-apoptotic protein CHOP was induced with TM, and not inhibited by vorinostat. Further, vorinostat did not prevent any renal damage or decline in renal function caused by tunicamycin. These data suggest that the protective mechanisms found by 4-PBA are primarily due to its molecular chaperone properties, and the HDAC inhibitors used did not provide any protection against renal injury caused by ER stress. |
| first_indexed | 2024-12-20T12:56:33Z |
| format | Article |
| id | doaj.art-7f32580d8efc46e9bf6cafe65956bdbf |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T12:56:33Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7f32580d8efc46e9bf6cafe65956bdbf2022-12-21T19:40:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011611e026051910.1371/journal.pone.0260519Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury.Rachel E CarlisleSalwa FarooqiMing Chan ZhangSarah LiuChao LuAndy PhanElise BrimbleJeffrey G DickhoutEndoplasmic reticulum (ER) stress is associated with acute kidney injury (AKI) caused by various mechanisms, including antibiotics, non-steroidal anti-inflammatory drugs, cisplatin, and radiocontrast. Tunicamycin (TM) is a nucleoside antibiotic that induces ER stress and is a commonly used model of AKI. 4-phenylbutyrate (4-PBA) is a chemical chaperone and histone deacetylase (HDAC) inhibitor and has been shown to protect the kidney from ER stress, apoptosis, and structural damage in a tunicamycin model of AKI. The renal protection provided by 4-PBA is attributed to its ability to prevent misfolded protein aggregation and inhibit ER stress; however, the HDAC inhibitor effects of 4-PBA have not been examined in the TM-induced model of AKI. As such, the main objective of this study was to determine if histone hyperacetylation provides any protective effects against TM-mediated AKI. The FDA-approved HDAC inhibitor vorinostat was used, as it has no ER stress inhibitory effects and therefore the histone hyperacetylation properties alone could be investigated. In vitro work demonstrated that vorinostat inhibited histone deacetylation in cultured proximal tubular cells but did not prevent ER stress or protein aggregation induced by TM. Vorinostat induced a significant increase in cell death, and exacerbated TM-mediated total cell death and apoptotic cell death. Wild type male mice were treated with TM (0.5 mg/kg, intraperitoneal injection), with or without vorinostat (50 mg/kg/day) or 4-PBA (1 g/kg/day). Mice treated with 4-PBA or vorinostat exhibited similar levels of histone hyperacetylation. Expression of the pro-apoptotic protein CHOP was induced with TM, and not inhibited by vorinostat. Further, vorinostat did not prevent any renal damage or decline in renal function caused by tunicamycin. These data suggest that the protective mechanisms found by 4-PBA are primarily due to its molecular chaperone properties, and the HDAC inhibitors used did not provide any protection against renal injury caused by ER stress.https://doi.org/10.1371/journal.pone.0260519 |
| spellingShingle | Rachel E Carlisle Salwa Farooqi Ming Chan Zhang Sarah Liu Chao Lu Andy Phan Elise Brimble Jeffrey G Dickhout Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury. PLoS ONE |
| title | Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury. |
| title_full | Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury. |
| title_fullStr | Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury. |
| title_full_unstemmed | Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury. |
| title_short | Inhibition of histone deacetylation with vorinostat does not prevent tunicamycin-mediated acute kidney injury. |
| title_sort | inhibition of histone deacetylation with vorinostat does not prevent tunicamycin mediated acute kidney injury |
| url | https://doi.org/10.1371/journal.pone.0260519 |
| work_keys_str_mv | AT rachelecarlisle inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT salwafarooqi inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT mingchanzhang inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT sarahliu inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT chaolu inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT andyphan inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT elisebrimble inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury AT jeffreygdickhout inhibitionofhistonedeacetylationwithvorinostatdoesnotpreventtunicamycinmediatedacutekidneyinjury |